Tags: cell biologycancer, cancer immunotherapy, cell biology, cell therapy, cytokines, interleukin, tumor microenvironmentCRSimmunotherapiesPoolbeg
| Profile | Contacts | Recent Articles on Subject | |
|---|---|---|---|
| 1 | Angus Chen STAT News Undignified, unfunny journalist. Health, cancer coverage at STAT News. | STAT+: For a leukemia that keeps returning, AbbVie drug may offer chance for a deep remission - 8 days ago | |
| 2 | John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California | Poolbeg Pharma presents positive results for POLB 001 - 12 days ago Poolbeg’s cytokine release syndrome drug shows potential - 11 months ago | |
| 3 | The Conversation Science Alert Science news. Official account. Australia | ||
| 4 | Ian Ingram MedPage Today Deputy Managing Editor.
MedPage Today. New York, New York | ||
| 5 | Judy George MedPage Today Medical reporter, writer. | Prion Disease Rising in the U.S. - about 1 year ago | |
| 6 | Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York | Novel Therapy Reduced Transfusion Dependence in Lower-Risk MDS - about 1 year ago Oncolytic Virus Shows High Response Rates in BCG-Unresponsive Bladder Cancer - about 1 year ago | |
| 7 | Hannah Thomasy, PhD The Scientist Freelance science writer. PhD. Seattle & Toronto | ||
| 8 | Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey | Researchers Assess Innate Immune System Changes Following Severe COVID-19 - about 1 year ago | |
| 9 | Aislinn Antrim, Assistant Managing Editor Pharmacy Times Journalist at Pharmacy Times. UNC graduate. | ||
| 10 | John Gever MedPage Today MedPage Today factotum. Pittsburgh, Pa. | Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus - 4 months ago Study Confirms: No Great Options for Treating VEXAS - 7 months ago COVID-19 Tied to Increased Risk for Rheumatic Disease - 10 months ago Why Is VEXAS Syndrome Often Fatal? Here's an Answer - about 1 year ago |